Cathepsin b deficiency attenuates cardiac remodeling in response to pressure overload via TNF-α/ASK1/JNK pathway

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 308, Issue 9, 2015, Pages H1143-H1154

  Wu, Qing Qing ^a,b   Xu, Man ^a,b   Yuan, Yuan ^a,b   Li, Fang Fang ^a,b   Yang, Zheng ^a,b   Liu, Yuan ^a,b   Zhou, Meng Qiao ^a,b   Bian, Zhou Yan ^a,b   Deng, Wei ^a,b   Gao, Lu ^c   Li, Hongliang ^a,b   Tang, Qi Zhu ^a,b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Apoptosis; Cardiac remodeling; Cathepsin B; Pressure overload

Indexed keywords

ANGIOTENSIN II; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; APOPTOSIS SIGNAL REGULATING KINASE 1; CATHEPSIN B; CYTOCHROME C; JANUS KINASE; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; CTSB PROTEIN, MOUSE; CTSB PROTEIN, RAT; MAP3K5 PROTEIN, MOUSE; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME DEFICIENCY; FEMALE; HEART DISEASE; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TISSUE REGENERATION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; FIBROSIS; GENETIC TRANSFECTION; GENETICS; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HEK293 CELL LINE; HUMAN; HYPERTROPHY, LEFT VENTRICULAR; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RNA INTERFERENCE;

ANIMALS; APOPTOSIS; CATHEPSIN B; DISEASE MODELS, ANIMAL; FEMALE; FIBROSIS; HEK293 CELLS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MAP KINASE KINASE KINASE 5; MICE, KNOCKOUT; MYOCYTES, CARDIAC; PROTEIN KINASE INHIBITORS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84929688306     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00601.2014     Document Type: Article

References (41)

1. Aoyagi T, Matsui T. Phosphoinositide-3 kinase signaling in cardiac hypertrophy and heart failure. Curr Pharm Des 17: 1818–1824, 2011.
2. Bao GY, Wang HZ, Shang YJ, Fan HJ, Gu ML, Xia R, Qin Q, Deng AM. Quantitative proteomic study identified cathepsin B associated with doxorubicin-induced damage in H9c2 cardiomyocytes. Biosci Trends 6: 283–287, 2012.
3. Baskin-Bey ES, Canbay A, Bronk SF, Werneburg N, Guicciardi ME, Nyberg SL, Gores GJ. Cathepsin B inactivation attenuates hepatocyte apoptosis and liver damage in steatotic livers after cold ischemia-warm reperfusion injury. Am J Physiol Gastrointest Liver Physiol 288: G396–G402, 2005.
4. Bhoopathi P, Chetty C, Gujrati M, Dinh DH, Rao JS, Lakka S. Cathepsin B facilitates autophagy-mediated apoptosis in SPARC overexpressed primitive neuroectodermal tumor cells. Cell Death Differ 17: 1529–1539, 2010.
5. Brenner C, Galluzzi L, Kepp O, Kroemer G. Decoding cell death signals in liver inflammation. J Hepatol 59: 583–594, 2013.
6. Chen GC, Zhao M, Lin S, Lu J, Kang J, Yu X. RIP1-dependent Bid cleavage mediates TNFa-induced but caspase-3-independent cell death in L929 fibroblastoma cells. Apoptosis 20: 92–109, 2015.
7. Cheng XW, Obata K, Kuzuya M, Izawa H, Nakamura K, Asai E, Nagasaka T, Saka M, Kimata T, Noda A, Nagata K, Jin H, Shi GP, Iguchi A, Murohara T, Yokota M. Elastolytic cathepsin induction activation system exists in myocardium and is upregulated in hypertensive heart failure. Hypertension 48: 979–987, 2006.
8. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 35: 569–582, 2000.
9. Feng Y, Ni L, Wang Q. Administration of cathepsin B inhibitor CA- 074Me reduces inflammation and apoptosis in polymyositis. J Dermatol Sci 72: 158–167, 2013.
10. Ge J, Zhao G, Chen R, Li S, Wang S, Zhang X, Zhuang Y, Du J, Yu X, Li G, Yang Y. Enhanced myocardial cathepsin B expression in patients with dilated cardiomyopathy. Eur J Heart Fail 8: 284–289, 2006.
11. Gjesdal O, Bluemke DA, Lima JA. Cardiac remodeling at the population level–risk factors, screening, and outcomes. Nat Rev Cardiol 8: 673–685, 2011.
12. Halade GV, Jin YF, Lindsey ML. Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. Pharmacol Ther 139: 32–40, 2013.
13. Ji W, Li Y, Wan T, Wang J, Zhang H, Chen H, Min W. Both internalization and AIP1 association are required for tumor necrosis factor receptor 2-mediated JNK signaling. Arterioscler Thromb Vasc Biol 32: 2271–2279, 2012.
14. Li XM, Ma YT, Yang YN, Liu F, Chen BD, Han W, Zhang JF, Gao XM. Downregulation of survival signalling pathways and increased apoptosis in the transition of pressure overload-induced cardiac hypertrophy to heart failure. Clin Exp Pharmacol Physiol 36: 1054–1061, 2009.
15. Liu A, Gao X, Zhang Q, Cui L. Cathepsin B inhibition attenuates cardiac dysfunction and remodeling following myocardial infarction by inhibiting the NLRP3 pathway. Mol Med Rep 8: 361–366, 2013.
16. Marswamy R, Thum T. Non-coding RNAs in cardiac remodeling and heart failure. Circ Res 113: 676–689, 2013.
17. Martinou JC, Youle RJ. Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev Cell 21: 92–101, 2011.
18. Mitra A, Basak T, Datta K, Naskar S, Sengupta S, Sarkar S. Role of a-crystallin B as a regulatory switch in modulating cardiomyocyte apoptosis by mitochondria or endoplasmic reticulum during cardiac hypertrophy and myocardial infarction. Cell Death Dis 4: e58, 2013.
19. Moles A, Tarrats N, Fernández-Checa JC, Marí M. Cathepsins B and D drive hepatic stellate cell proliferation and promote their fibrogenic potential. Hepatology 49: 1297–1307, 2009.
20. Müller AL, Dhalla NS. Role of various proteases in cardiac remodeling and progression of heart failure. Heart Fail Rev 17: 395–409, 2012.
21. Musil D, Zucic D, Turk D, Engh RA, Mayr I, Huber R, Popovic T, Turk V, Towatari T, Katunuma N, Bode W. The refined 2.15 A X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity. EMBO J 10: 2321–2330, 1991.
22. Niu D, Jin K, Wang L, Sun F, Li J. Identification of cathepsin B in the razor clam Sinonovacula constricta and its role in innate immune responses. Dev Comp Immunol 41: 94–99, 2013.
23. Porter K, Lin Y, Liton PB. Cathepsin B is up-regulated and mediates extracellular matrix degradation in trabecular meshwork cells following phagocytic challenge. PLoS One 8: e68668, 2013.
24. Rao JS, Gondi CS. Cathepsin B as a cancer target. Expert Opin Ther Targets 17: 281–291, 2013.
25. Ren R, Oakley RH, Cruz-Topete D, Cidlowski JA. Dual role for glucocorticoids in cardiomyocyte hypertrophy and apoptosis. Endocrinology 153: 5346–5360, 2012.
26. Rohini A, Agrawal N, Koyani CN, Singh R. Molecular targets and regulators of cardiac hypertrophy. Pharmacol Res 61: 269–280, 2010.
27. Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, Kopinja J, Rooney DL, Zhang M, Ihrig MM, McManus MT, Gertler FB, Scott ML, Van Parijs L. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 33: 401–406, 2003.
28. Schenke-Layland K, Stock UA, Nsair A, Xie J, Angelis E, Fonseca CG, Larbig R, Mahajan A, Shivkumar K, Fishbein MC, MacLellan WR. Cardiomyopathy is associated with structural remodelling of heart valve extracellular matrix. Eur Heart J 30: 2254–2265, 2009.
29. Stoka V, Turk B, Schendel SL, Kim TH, Cirman T, Snipas SJ, Ellerby LM, Bredesen D, Freeze H, Abrahamson M, Bromme D, Krajewski S, Reed JC, Yin XM, Turk V, Salvesen GS. Lysosomal protease pathways to apoptosis. Cleavage of bid, not pro-caspases, is the most likely route. J Biol Chem 276: 3149–3157, 2001.
30. Sun M, Chen M, Dawood F, Zurawska U, Li JY, Parker T, Kassiri Z, Kirshenbaum LA, Arnold M, Khokha R, Liu PP. Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation 115: 1398–1407, 2007.
31. Sun M, Ouzounian M, de Couto G, Chen M, Yan R, Fukuoka M, Li G, Moon M, Liu Y, Gramolini A, Wells GJ, Liu PP. Cathepsin-L ameliorates cardiac hypertrophy through activation of the autophagylysosomal dependent protein processing pathways. J Am Heart Assoc 2: e000191, 2013.
32. Tan Q, Cai J, Shen D, Bian Z, Yan L, Wang YX, Lan J, Zhuang GQ, Ma WZ, Wang W. Lysosomal cysteine peptidase cathepsin L protects against cardiac hypertrophy through blocking AKT/GSK3beta signaling. J Mol Med 87: 249–260, 2009.
33. Turk V, Turk B, Turk D. Lysosomal cysteine proteases: facts and opportunities. EMBO J 3: 17, 2001.
34. Umadevi S, Gopi V, Elangovan V. Regulatory mechanism of gallic acid against advanced glycation end products induced cardiac remodeling in experimental rats. Chem Biol Interact 5: 28–36, 2013.
35. Ventura A, Meissner A, Dillon CP, McManus M, Sharp PA, Van Parijs L, Jaenisch R, Jacks T. Cre-lox-regulated conditional RNA interference from transgenes. Proc Natl Acad Sci USA 101: 10380–10385, 2004.
36. Walther S, Awad S, Lonchyna VA, Blatter LA. NFAT transcription factor regulation by urocortin II in cardiac myocytes and heart failure. Am J Physiol Heart Circ Physiol 306: H856–H866, 2014.
37. Wu J, You J, Wang S, Zhang L, Gong H, Zou Y. Insights into the activation and inhibition of angiotensin II type 1 receptor in the mechanically loaded heart. Circ J 78: 1283–1289, 2014.
38. Xu H, Yao Y, Su Z, Yang Y, Kao R, Martin CM, Rui T. Endogenous HMGB1 contributes to ischemia-reperfusion-induced myocardial apoptosis by potentiating the effect of TNF-[1]/JNK. Am J Physiol Heart Circ Physiol 300: H913–H921, 2011.
39. Yan L, Wei X, Tang QZ, Feng J, Zhang Y, Liu C, Bian ZY, Zhang LF, Chen M, Bai X, Wang AB, Fassett J, Chen Y, He YW, Yang Q, Liu PP, Li H. Cardiac-specific mindin overexpression attenuates cardiac hypertrophy via blocking AKT/GSK3b and TGF-b1-Smad signalling. Cardiovasc Res 92: 85–94, 2011.
40. Yang B, Ye D, Wang Y. Caspase-3 as a therapeutic target for heart failure. Expert Opin Ther Targets 17: 255–263, 2013.
41. Zhou J, Xu X, Liu JJ, Lin YX, Gao GD. Angiotensin II receptors subtypes mediate diverse gene expression profile in adult hypertrophic cardiomyocytes. Clin Exp Pharmacol Physiol 34: 1191–1198, 2007.